ELUT Overview

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.

Wall Street analysts forecast ELUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELUT is3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Elutia Inc revenue for the last quarter amounts to 3.27M USD, increased 16.16

Elutia Inc. EPS for the last quarter amounts to 1.34 USD, decreased -615.38

Elutia Inc (ELUT) has 25 emplpoyees as of March 31 2026.

Today ELUT has the market capitalization of 45.78M USD.